lncRNA SNHGs在前列腺癌发生发展中的研究进展

doi:10.11904/j.issn.1002-3070.2020.05.011

摘要/Abstract

摘要： 前列腺癌已成为威胁老年男性健康的全球性“杀手”,其发生发展机制以及治疗方法是当前的研究重点。近年来,基因转录或转录后调控机制被证明在前列腺癌进展中发挥关键的作用,其中长链非编码RNA(long non-coding RNA,lncRNA)扮演着重要的角色。lncRNA SNHGs与前列腺癌关系密切,其不仅影响肿瘤生物学特性,在前列腺癌细胞凋亡、自噬、侵袭、细胞增殖等方面发挥至关重要的作用,而且与肿瘤预后相关。其作用机制与ceRNA学说、Wnt/β-catenin、PI3K/AKT/mTOR等信号通路有关。本文就lncRNA SNHGs在前列腺癌发生发展中的作用做一综述,希望能为前列腺癌的诊治提供新思路。

关键词: 长链非编码RNA, 前列腺癌, 竞争性内源性RNA

Abstract: Prostate cancer has become a global“killer”that threatens the health of elderly men.The mechanism and treatment of its occurrence and development are the current research focuses.In recent years,gene transcription or post-transcriptional regulatory mechanisms have been shown to play a key role in the progression of prostate cancer,of which long non-coding RNA(lncRNA)plays an important role.lncRNA SNHGs are closely related to prostate cancer.They not only affect the biological characteristics of tumors,playing a vital role in the apoptosis,autophagy,invasion,and cell proliferation of prostate cancer cells,but they also are related to tumor prognosis.Its mechanism of action is related to ceRNA,Wnt/β-catenin,PI3K/AKT/mTOR and other signaling pathways.This article reviews the role of LncRNA SNHGs in the occurrence and development of prostate cancer,hoping to provide new ideas for the diagnosis and treatment of prostate cancer.

Key words: Long non-coding RNA, Prostate cancer, Competitive endogenous RNA

中图分类号:

R737.25

苗鹏程, 康印东, 李富东, 孟冬冬, 王东星, 常德辉. lncRNA SNHGs在前列腺癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 446-450.

MIAO Pengcheng, KANG Yindong, LI Fudong, MENG Dongdong, WANG Dongxing, CHANG Dehui. Research progress of lncRNA SNHGs in the occurrence and development of prostate cancer[J]. Journal of Practical Oncology, 2020, 34(5): 446-450.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.05.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I5/446

参考文献

1 Isaac C,Patel TR,Zovoilis A.Non-coding RNAs in virology:an RNA genomics approach[J].Biotechnol Genet Eng Rev,2018,34(1):90-106.
2 Fawzy MS,Abu-AlSel BT,Al-Ageeli E,et al.Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis:a preliminary cross-sectional analysis[J].Arch Physiol Biochem,2020,126(2):172-182.
3 Yan Y,Fan Q,Wang L,et al.lncRNA Snhg1,a non-degradable sponge for miR-338,promotes expression of proto-oncogene CST3 in primary esophageal cancer cells[J].Oncotarget,2017,8(22):35750-35760.
4 Djebali S,Davis CA,Merkel A,et al.Landscape of transcription in human cells[J].Nature,2012,489(7414):101-108.
5 郭永东,靳晶,李利敏,等.分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2020,34(1):69-73.
6 Esteller M.Non-coding RNAs in human disease[J].Nat Rev Genet,2011,12(12):861-874.
7 Fatica A,Bozzoni I.Long non-coding RNAs:new players in cell differentiation and development[J].Nat Rev Genet,2014,15(1):7-21.
8 Busch H,Reddy R,Rothblum L,et al.SnRNAs,SnRNPs,and RNA processing[J].Annu Rev Biochem,1982,51:617-654.
9 Kiss T.Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs[J].EMBO J,2001,20(14):3617-3622.
10 Massenet S,Bertrand E,Verheggen C,et al.Assembly and trafficking of box C/D and H/ACA snoRNPs[J].RNA Biol,2017,14(6):680-692.
11 Gong J,Li Y,Liu CJ,et al.A pan-cancer analysis of the expression and clinical relevance of small nucleolar RNAs in human cancer[J].Cell Rep,2017,21(7):1968-1981.
12 Askarian-Amiri ME,Crawford J,French JD,et al.SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer[J].RNA,2011,17(5):878-891.
13 Wang X,He C,Yang Z,et al.Dysregulation of long non-coding RNA SNHG12 alters the viability,apoptosis,and autophagy of prostate cancer cells by regulating miR-195/CCNE1 axis[J].Int J Clin Exp Pathol,2019,12(4):1272-1283.
14 Song J,Wu X,Ma R,et al.Long noncoding RNA SNHG12 promotes cell proliferation and activates Wnt/β-catenin signaling in prostate cancer through sponging microRNA-195[J].J Cell Biochem,2019,120(8):13066-13075.
15 Han Y,Hu H,Zhou J,et al.Knockdown of LncRNA SNHG7 inhibited epithelial-mesenchymal transition in prostate cancer though miR-324-3p/WNT2B axis in vitro[J].Pathol Res Pract,2019,215(10):152537.
16 Qi H,Wen B,Wu Q,et al.Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503[J].Biomed Pharmacother,2018,102:326-332.
17 Zhang Y,Zhang D,Lv J,et al.LncRNA SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBP1A axis[J].Gene,2019,705:44-50.
18 Wu X,Xiao Y,Zhou Y,et al.lncRNA SNHG20 promotes prostate cancer migration and invasion via targeting the miR-6516-5p/SCGB2A1 axis[J].Am J Transl Res,2019,11(8):5162-5169.
19 Li J,Zhang Z,Xiong L,et al.SNHG1 lncRNA negatively regulates miR-199a-3p to enhance CDK7 expression and promote cell proliferation in prostate cancer[J].Biochem Biophys Res Commun,2017,487(1):146-152.
20 Xie M,Zhang Z,Cui Y,et al.Long Noncoding RNA SNHG1 contributes to the promotion of prostate cancer cells through regulating miR-377-3p/AKT2 Axis[J].Cancer Biother Radiopharm,2020[Epub ahead of print].
21 Lee J,Ryu J,Lee C,et al.Strong cis-acting expression quantitative trait loci for the genes encoding SNHG5 and PEX6[J].Medicine(Baltimore),2016,95(52):e5793.
22 Ye G,Guo L,Xing Y,et al.Identification of prognostic biomarkers of prostate cancer with long non-coding RNA-mediated competitive endogenous RNA network[J].Exp Ther Med,2019,17(4):3035-3040.
23 Sun B,Ke KB,Liu DF,et al.Long noncoding RNA SNHG14 acts as an oncogene in prostate cancer via targeting miR-613[J].Eur Rev Med Pharmacol Sci,2020,24(2):633-638.
24 Cheng G,Song Z,Liu Y,et al.Long noncoding RNA SNHG12 indicates the prognosis of prostate cancer and accelerates tumorigenesis via sponging miR-133b[J].J Cell Physiol,2020,235(2):1235-1246.
25 Xia Q,Li J,Yang Z,et al.Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer[J].Medicine(Baltimore),2020,99(7):e18993.
26 Catalona WJ,Smith DS,Ratliff TL,et al.Measurement of prostate-specific antigen in serum as a screening test for prostate cancer[J].N Engl J Med,1991,324(17):1156-1161.
27 Stamey TA,Caldwell M,McNeal JE,et al.The prostate specific antigen era in the United States is over for prostate cancer:what happened in the last 20 years[J].J Urol,2004,172(4 Pt 1):1297-1301.
28 Loeb S,Gashti SN,Catalona WJ.Exclusion of inflammation in the differential diagnosis of an elevated prostate-specifc antigen(PSA)[J].Urol Oncol,2009,27(1):64-66.
29 Djavan B,Zlotta A,Remzi M,et al.Optimal predictors of prostate cancer on repeat prostate biopsy:a prospective study of 1,051 men[J].J Urol,2000,163(4):1144-1148.
30 Andriole GL,Crawford ED,Grubb RL,et al.Mortality results from a randomized prostate-cancer screening trial[J].N Engl J Med,2009,360(13):1310-1319.
31 Salmena L,Poliseno L,Tay Y,et al.A ceRNA hypothesis:the Rosetta Stone of a hidden RNA language[J].Cell,2011,146(3):353-358.
32 Fabian MR,Sonenberg N,Filipowicz W.Regulation of mRNA translation and stability by microRNAs[J].Annu Rev Biochem,2010,79:351-379.
33 Ebert MS,Sharp PA.MicroRNA sponges:progress and possibilities[J].RNA,2010,16(11):2043-2050.
34 Arvey A,Larsson E,Sander C,et al.Target mRNA abundance dilutes microRNA and siRNA activity[J].Mol Syst Biol,2010,6:363.
35 Ding S,Qu W,Jiao Y,et al.lncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway[J].Cancer Biomark,2018,22(2):217-226.
36 Karar J,Maity A.PI3K/AKT/mTOR Pathway in Angiogenesis[J].Front Mol Neurosci,2011,4:51.
37 Sarker D,Reid AH,Yap TA,et al.Targeting the PI3K/AKT pathway for the treatment of prostate cancer[J].Clin Cancer Res,2009,15(15):4799-4805.
38 Morgan TM,Koreckij TD,Corey E,et al.Targeted therapy for advanced prostate cancer:inhibition of the PI3K/Akt/mTOR pathway[J].Curr Cancer Drug Targets,2009,9(2):237-249.
39 Yan Y,Chen Z,Xiao Y,et al.Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis[J].Mol Biol Rep,2019,46(3):2771-2778.

[1]	程月, 张明岩, 张文博, 徐晖. LncRNAs作为ceRNAs在肺癌中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 451-455.
[2]	仝潇, 邢佳妮, 王丽虹. 长链非编码RNA HCP5通过调控凋亡通路促进三阴性乳腺癌的研究[J]. 实用肿瘤学杂志, 2020, 34(4): 321-327.
[3]	李静, 王玉霞, 陈杰. 长链非编码RNA HOTAIR在宫颈癌中的相关研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 368-371.
[4]	郭永东, 靳晶, 李利敏, 贺宇彤. 分化拮抗非蛋白质编码RNA(DANCR)在常见恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 69-73.
[5]	刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.
[6]	李思维 , 庞达. 长链非编码RNA(lncRNA)在癌症中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 471-475.
[7]	赵金璐, 李国东刘明. 长链非编码RNA CCAT1与消化系统恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 367-370.
[8]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[9]	姜涛, 张旭. 孤儿核受体在前列腺癌中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 377-380.
[10]	徐文品, 焦琨(综述), 张伟(审校). 长链非编码RNAs在口腔鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 258-262.
[11]	杨钊, 赵世光. 长链非编码RNA CASC2抑制肿瘤发生发展的研究概况[J]. 实用肿瘤学杂志, 2018, 32(2): 179-183.
[12]	张中民, 庞达. 长链非编码RNA调控癌症细胞信号通路的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 184-188.
[13]	余嘉惠, 刘煊, 李琦, 陆烨, 岳小强. 长链非编码RNA在胃癌中的调控机制及中药对其作用的研究概况[J]. 实用肿瘤学杂志, 2018, 32(1): 47-52.
[14]	申美莹, 庞达. 长链非编码RNA在肿瘤微环境中的调控作用[J]. 实用肿瘤学杂志, 2018, 32(1): 73-76.
[15]	陈芊霖，庞达. 长链非编码RNA EPB41L4A-AS2对乳腺癌的预后研究[J]. 实用肿瘤学杂志, 2017, 31(3): 205-210.